Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A global network for network medicine

Network Medicine is now an established scientific discipline, having generated key insights on integrated mechanisms underlying complex human diseases. The next discovery phase will emphasize innovating analytics that optimize networks for advancing precision medicine. Accomplishing this goal will require organizing a scientifically diverse team studying big datasets shared globally.

Introduction

Network Medicine is a scientific discipline that focuses on the interaction between biological components, such as proteins, microRNAs, or metabolites, to understand molecular pathways that underlie the pathogenesis of diseases. More recently, Network Medicine has expanded to integrate molecular data with phenotypic features as a means by which to clarify mechanisms driving clinical disorders. Since the first publication introducing Network Medicine in 20071, nearly 3300 scientific reports have advanced and refined this discipline, which aims to use scientific “big data” to decipher the role of molecular interactions in the context of health and human disease.

Originating in yeast two-hybrid and tandem affinity purification systems as a means to create protein-protein interaction networks, the arc of Network Medicine has evolved greatly. This evolution includes, for example, demonstrating that clinical disorders previously regarded as dissimilar, in fact, share common protein connectivity features, and informing point-of-care risk stratification tools. Increasingly, Network Medicine is working with ever-larger molecular and phenotypic datasets, and moving into the realm of networks of networks. Both static and dynamic features of these increasingly complex structures will be essential for realizing the field’s full potential in biomedicine. Diversity in Network Medicine analytics has proved gainful2, but has given rise to new challenges that must be met in order to optimize the extensive intellectual and data resources available world-wide. Indeed, international efforts in Network Medicine have been somewhat fragmented, hindering opportunity to advance the field maximally. To address this crossroads, the first International Conference on Network Medicine and Big Data assembled in Rome, Italy, in 2018, and determined that an organized scientific approach to Network Medicine, inclusive of international input functioning synergistically, is needed. This goal is particularly timely considering that access to increasingly complex omics platforms will define scientific eras to come, thereby shifting emphasis from acquisition of data to integrative analysis of data as viewed through a network lens.

Goals and Strategic Overview of Network Medicine

In the last decade, translational research has established multidisciplinary mindsets, thus widening the cultural and scientific opportunities of individual researchers. Despite these gains, translating biological insights to human disease diagnosis and therapeutics remains stagnant. One principal reason for this dilemma may be inherent to conventional, reductionist approaches used for scientific problem solving. Indeed, Network Medicine is antithetical to this time-honored approach, focusing on integrating different layers of information to ascertain the inherent and mechanistically relevant connectivity among biological components. It is in this way that phenotype alignment with pathobiological substrate is often superior, albeit reorganized, as compared to stochastic or probabilistic modeling of simple associations alone3.

A distinguishing feature of Network Medicine is the incorporation of all information layers to define pathophenotypes, which is accomplished by expanding data dimensions4. Thus, biases commonly ascribed to viewing complex diseases through the prism of a single sentinel event, often a genetic variant, do not exist. In contrast, focusing on protein-protein interactions (as one example) that (i) regulate specific endophenotypes and (ii) facilitate cross-talk between pathways that influence different endophenotypes permits a flexible paradigm inclusive of, but not solely due to, genetic context5. The smallest cluster (disease network module) of information within a larger interactome is identifiable, and can be used to discover unique features for disease classification, therapeutic targeting, or drug repurposing2.

Network Medicine is well-positioned to advance personalized medicine since the method itself is based on tightly linked functional relationships among epigenomic, transcriptomic, post-transcriptional, proteomic, and metabolomic data. Derivative patterns, including cutting-edge strategies6 to individualize datasets tied to patient reticulotypes (i.e., individualized disease modules specific to a patient), offer promising insight into the clinical implications of patient-specific mechanistic biological signatures. Pursuing this strategy will prove important toward developing an optimal health management strategy for aging societies, in particular, for which chronic non-communicable diseases will affect most populations.

International Network Medicine Consortium (INMC)

The INMC aims to balance hypothesis-driven and data (methodology)-driven approaches to healthcare applications, leveraging the creativity of group members whose expertise is rooted deeply in knowledge of network science, computer science, physics, mathematics, biology, pathophysiology, and clinical medicine. There are three principal scientific goals of the INMC: (1) to explain single cell functions and cell-cell interactions that determine the behavior of the whole organism, and how the whole organism interacts with its environment to maintain homeostasis, which ultimately degenerates into disease states; (2) to apply this information to foster new diagnostic tools, preventive strategies, and therapeutic targets, and to discover new drugs and repurpose approved drugs; and (3) to integrate biological and physiological information contained in networks to discover mechanistically new disease subgroups, enhance patient risk stratification, and develop individualized treatment strategies.

Creating and validating these models requires wide-ranging skill sets, from which analytical pipelines can emerge: (i) data sorting, aggregation, and network construction and analysis; (ii) modeling dynamic interactions; and (ii) translating and confirming data application to biomedical systems. These processes will require critical input from biologists, physicians, computer scientists, physicists, mathematicians, and statisticians. Thus, the creation of the INMC may advance research quality and reproducibility, and lead to a unified understanding of disease mechanisms. An initial focus will be on synchronization and integration in sharing data, creating protocols for evaluating patients so that deep clinical phenotypic data are usable in network analysis, and integrative experimental design. To ensure a stable stream of diverse intellectual input, formal training courses, workshops, and outreach science communication activities will be available for interested stakeholders.

Model for scientific discovery

The INMC model includes four distinct, but interacting, components: methods, molecular network profiles, phenotype network profiles, and machine learning and artificial intelligence. In methods, properties of complex networks that can be segmented into sub-networks (n-partite networks) are considered, and the relevance of data determined by network theory informs likelihoods, and, thereby, significance scores. In molecular network profiles, genes, proteins, and other molecular data types are used to reveal fundamental biological relationships resulting in a unique network wiring pattern that is the basis for any given disease. Correlation-based, gene regulatory, Bayesian, and protein-protein interaction networks are used; some networks connect diseases to associated factors outside the human cell, and parallel networks of environmental and genetic etiological factors (networks of networks) linked with shared diseases inform the ‘etiome’. Clustering environmental factors in these networks stands to provide critical data on acquired (modifiable) disease triggers, often lacking in conventional reports7.

In phenotype network profiles, interactome networks are used to refine disease classification, discover molecular targets for drug repurposing, and establish novel therapeutics8,9. Emphasizing disease network modules, which are neighborhoods or subnetworks of components in the interactome that, if disrupted or altered, result in specific pathophenotypes, has already proven to be insightful10. Patient-level clinical phenotyping based on networks that include functionally related physiological parameters is also informative, but underutilized11. Machine learning focuses on regularities in clinical or molecular data, and is a useful strategy by which to filter network instruments, such as minimal spanning trees or deregulated sub-network identification12, in order to identify mechanotypes and novel endophenotypes13.

The INMC is an emerging consortium leveraging global intellectual and data resources to create a highly interdisciplinary environment for expanding the discipline of Network Medicine in research, education, and clinical care. By integrating contemporary methodologies, biological platforms, computational technologies, and global intellectual resources, the INMC mission is to refine knowledge of disease pathogenesis and advance drug discovery. Meeting this goal will likely require including an expansive but rational approach to studying biological as well as socioeconomic, nutritional, wellness, and other datasets yielding information on acquired risk for disease. In addition and importantly, for the full adoption of Network Medicine by the biomedical community, novel strategies for training and education will need to be developed. In doing so, challenging, effective, and attainable goals have been set for the next phases of Network Medicine, which promise to revolutionize concepts in medical research for the purpose of optimizing disease treatment and outcome.

References

  1. 1.

    Barabási, A. L. Network medicine–from obesity to the “diseasome”. N. Engl. J. Med. 57, 404–407 (2007).

    Article  Google Scholar 

  2. 2.

    Menche., J. et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601 (2015).

    Article  Google Scholar 

  3. 3.

    Halu, A. et al. Exploring the cross-phenotype network region of disease modules reveals concordant and discordant pathways between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Hum. Mol. Genet. 28, 2352–2364 (2019).

    CAS  Article  Google Scholar 

  4. 4.

    Lee, L. Y. & Loscalzo, J. Network medicine in pathobiology. Am. J. Pathol. 189, 1311–1326 (2019).

    Article  Google Scholar 

  5. 5.

    Maron, B. J., Maron, M. S., Maron, B. A. & Loscalzo, J. Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 73, 1978–1986 (2019).

    Article  Google Scholar 

  6. 6.

    Liu, X., Wang, Y., Ji, H., Aihara, K. & Chen, L. Personalized characterization of diseases using sample-specific networks. Nucleic Acids Res. 44, e164 (2016).

    Article  Google Scholar 

  7. 7.

    Liu, Y. I., Wise, P. H. & Butte, A. J. The “etiome”: identification and clustering of human disease etiological factors. BMC Bioinformatics 10, S14 (2009).

    Article  Google Scholar 

  8. 8.

    Cheng, F. et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 9, 2691 (2018).

    Article  Google Scholar 

  9. 9.

    Casas, A. I. et al. From single drug targets to synergistic network pharmacology in ischemic stroke. Proc. Natl Acad. Sci. USA 116, 7129–7136 (2019).

    CAS  Article  Google Scholar 

  10. 10.

    Zhou, X., Menche, J., Barabási, A. L. & Sharma, A. Human symptoms–disease network. Nat. Commun. 5, 4212 (2014).

    CAS  Article  Google Scholar 

  11. 11.

    Oldham, W. M. et al. Network analysis to risk stratify patients with exercise intolerance. Circ. Res. 122, 864–876 (2018).

    CAS  Article  Google Scholar 

  12. 12.

    González, G. et al. Disease staging and prognosis in smokers using deep learning in chest computed tomography. Am. J. Respir. Crit. Care Med. 197, 193–203 (2018).

    Article  Google Scholar 

  13. 13.

    Alcaraz, N. et al. De novo pathway-based biomarker identification. Nucleic Acid Res. 45, e151 (2017).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Consortia

Contributions

J.L.: Conceptual design, manuscript drafting, editing, and final approval, accountable for all aspects of the work. B.A.M.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work. L.A.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work. J.-L.B.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work. J.B.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work. P.F.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work. S.F.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work. P.P.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work. E.P.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work, E.K.S.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work, A.-L.B.: Conceptual design, drafting, editing, and final approval, accountable for all aspects of the work.

Corresponding author

Correspondence to Joseph Loscalzo.

Ethics declarations

Competing interests

B.A.M.: Consultant for Actelion Pharmaceuticals for a project unrelated to this current work; co-inventor on U.S. patent pending PCT/US2019/059890 and U.S. patent 9,605,047, which are not related to the current work. P.F.: Founder and CEO of Pharmahungary Group, a group of R&D companies. E.S.: In the past 3 years, he has received institutional grant support from GSK and Bayer. A.L.B.: is the founder of Scipher, Foodome and Nomix, companies that are using tools of network science to make an impact on health. J.L.: Co-founder of Scipher (for profit) Scientific Advisory Board (2013-to present), and consulting services. The remaining authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Maron, B.A., Altucci, L., Balligand, JL. et al. A global network for network medicine. npj Syst Biol Appl 6, 29 (2020). https://doi.org/10.1038/s41540-020-00143-9

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing